However, the precise role and utility of TMB as a predictive biomarker for the efficacy of PD-1/PD-L1 inhibitors in NSCLC remain a matter of ongoing debate.[6] While several studies have suggested a positive correlation between high TMB and improved clinical response to PD-1/PD-L1 blockade, others have reported conflicting findings, highlighting the need for further investigation of the complex interplay between TMB, immune response, and therapeutic efficacy in NSCLC.[7,8]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.